Top 6 Veterinary Prescription Heart and Blood Pressure Medications for Dogs in Canada - 2025 Veterinary Guide to ACE Inhibitors, Beta-Blockers, Diuretics, Vasodilators & Antiarrhythmics with Dosing, Monitoring and Combination Therapy

Vetmedin (pimobendan) is a market leader in canine cardiac care as a positive inotrope and vasodilator frequently used alongside ACE inhibitors to improve clinical outcomes in congestive heart failure. Although not an ACE inhibitor itself, its clear survival and quality-of-life benefits make it a standard complementary therapy to the ACE products listed here, and its established efficacy can reduce downstream treatment costs by stabilizing patients more quickly. Practically, clinicians favor pairing Vetmedin with ACE inhibitors for a combined pharmacologic strategy rather than as a standalone blood-pressure agent.

Fortekor (benazepril) is an ACE inhibitor rather than an ARB, but it remains a widely used, well-studied and generally lower-cost prescription for canine cardiovascular disease and proteinuria. Clinicians frequently choose it as a financially attractive first-line therapy; however, dogs intolerant to ACE inhibitors or those needing direct angiotensin II receptor blockade may benefit more from ARBs like telmisartan, losartan or irbesartan despite their higher cost or compounded status.

Propranolol 10mg is a commonly used small-dose, non-selective beta blocker favored when clinicians require both peripheral and central beta blockade in small dogs, and its low strength facilitates fine dosing adjustments. Its higher lipophilicity relative to atenolol provides different therapeutic effects in some arrhythmic or stress-related indications, though this can also increase the potential for central side effects and monitoring needs. Financially it is typically low-cost per tablet, making it a practical choice for short-term or adjunctive therapy compared with the more specialized and expensive sotalol.

Lasix is the long-standing market leader for acute and chronic diuretic management in dogs because of its rapid, potent loop diuretic effect and widespread veterinary familiarity; it is especially effective for acute pulmonary edema and congestive heart failure. Compared with other agents on this list it offers the lowest acquisition cost per dose and a predictable IV/oral dosing profile, though it lacks the potassium-sparing and RAAS-modifying properties of spironolactone and the longer duration of torsemide.

The compounded hydralazine oral suspension is a market-leading choice for small or pill-averse dogs because it enables precise, weight‑based dosing and palatable formulations that standard tablets cannot match. Although compounding increases per-unit cost relative to off-the-shelf Apresoline tablets, the technical advantage of customizable concentrations and flavored liquids makes it superior for pediatric, geriatric, or outpatient titration scenarios where dosing flexibility and adherence matter most.

Sildenafil (generic) is the principal pulmonary vasodilator in canine combination cardiac therapy, providing targeted reduction of pulmonary artery pressure and improving exercise tolerance in dogs with pulmonary hypertension. Although generally more expensive than atenolol and sometimes requiring additional monitoring when co-administered, its technical advantage in directly addressing pulmonary vascular resistance makes it a complementary agent to beta-blockers and spironolactone in multi-drug regimens.